Astex Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report
Astex Pharmaceuticals, Inc. %li%Strategy, SWOT and Corporate Finance Report
Summary
Astex Pharmaceuticals, Inc. %li%Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.
Key Highlights
Astex Pharmaceuticals, Inc. (Astex or ‘the company’), a member of Otsuka Group, discovers, develops and commercializes cancer and central nervous system (CNS) therapies. It offers oncology product portfolio with multiple drugs in mid-late stage clinical development worldwide and CNS product portfolio of novel targeted therapeutics for defined neurodegenerative disease populations. Its product pipeline includes), a next generation DNA-hypomethylating agent; ASTX727, TAS1553, TAS1440, Azacitidine and Cedazuridine (ASTX030), an oral DNMT (DNA methyltransferase) inhibitor; ASTX029, an inhibitor of ERK 1/2; and ASTX660, a dual IAP (inhibitors of apoptosis proteins) antagonist. Astex has business presence in the UK and the US. The company is headquartered in Pleasanton, California, the US.
Scope
Summary
Astex Pharmaceuticals, Inc. %li%Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.
Key Highlights
Astex Pharmaceuticals, Inc. (Astex or ‘the company’), a member of Otsuka Group, discovers, develops and commercializes cancer and central nervous system (CNS) therapies. It offers oncology product portfolio with multiple drugs in mid-late stage clinical development worldwide and CNS product portfolio of novel targeted therapeutics for defined neurodegenerative disease populations. Its product pipeline includes), a next generation DNA-hypomethylating agent; ASTX727, TAS1553, TAS1440, Azacitidine and Cedazuridine (ASTX030), an oral DNMT (DNA methyltransferase) inhibitor; ASTX029, an inhibitor of ERK 1/2; and ASTX660, a dual IAP (inhibitors of apoptosis proteins) antagonist. Astex has business presence in the UK and the US. The company is headquartered in Pleasanton, California, the US.
Scope
- Detailed information on Astex Pharmaceuticals, Inc. required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Astex Pharmaceuticals, Inc. in the form of a SWOT analysis
- An in-depth view of the business model of Astex Pharmaceuticals, Inc. including a breakdown and examination of key business segments
- Intelligence on Astex Pharmaceuticals, Inc.'s mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Astex Pharmaceuticals, Inc., such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
- Gain understanding of Astex Pharmaceuticals, Inc. and the factors that influence its strategies.
- Track strategic initiatives of the company and latest corporate news and actions.
- Assess Astex Pharmaceuticals, Inc. as a prospective partner, vendor or supplier.
- Support sales activities by understanding your customers' businesses better.
- Stay up to date on Astex Pharmaceuticals, Inc.'s business structure, strategy and prospects.
Company Snapshot
Astex Pharmaceuticals, Inc.: Company Overview
Astex Pharmaceuticals, Inc.: Overview and Key Facts
Astex Pharmaceuticals, Inc.: Overview
Astex Pharmaceuticals, Inc.: Key Facts
Astex Pharmaceuticals, Inc.: Key Employees
Astex Pharmaceuticals, Inc.: Key Employee Biographies
Astex Pharmaceuticals, Inc.: Major Products and Services
Astex Pharmaceuticals, Inc.: Company History
Astex Pharmaceuticals, Inc.: Management Statement
Astex Pharmaceuticals, Inc.: Locations and Subsidiaries
Astex Pharmaceuticals, Inc.: Key Competitors
Astex Pharmaceuticals, Inc.: Company Analysis
Astex Pharmaceuticals, Inc.: Business Description
Astex Pharmaceuticals, Inc.: SWOT Analysis
Astex Pharmaceuticals, Inc.: SWOT Overview
Astex Pharmaceuticals, Inc.: Strengths
Astex Pharmaceuticals, Inc.: Weaknesses
Astex Pharmaceuticals, Inc.: Opportunities
Astex Pharmaceuticals, Inc.: Threats
Astex Pharmaceuticals, Inc.: Corporate Financial Deals Activity
Astex Pharmaceuticals, Inc.: Financial Deals Overview
Astex Pharmaceuticals, Inc.: Targets and Partners
Astex Pharmaceuticals, Inc.: Top Deals 2019 - 2023YTD*
Astex Pharmaceuticals, Inc.: Partnership
Astex Pharmaceuticals, Inc.: Recent Developments
Astex Pharmaceuticals, Inc.: News and Events Summary
Astex Pharmaceuticals, Inc.: Corporate Governance
Astex Pharmaceuticals, Inc.: Financial Deals
Astex Pharmaceuticals, Inc.: Market Developments
Astex Pharmaceuticals, Inc.: Research & Development
Appendix
Contact Us
Methodology
About MarketLine
LIST OF TABLES
Table 1: Astex Pharmaceuticals, Inc.: Key Facts
Table 2: Astex Pharmaceuticals, Inc.: Key Employees
Table 3: Astex Pharmaceuticals, Inc.: Company History
Table 4: Astex Pharmaceuticals, Inc.: Locations and Subsidiaries
Table 5: Astex Pharmaceuticals, Inc.: Key Competitors
Table 6: Astex Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (TTM*)
Table 7: Astex Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (2019 - YTD*2023)
Table 8: Astex Pharmaceuticals, Inc.: Targets and Partners
Table 9: Astex Pharmaceuticals, Inc.: Top Deals 2019 - 2023YTD*
Table 10: Astex Pharmaceuticals, Inc.: Partnership Volume and Value Trend (2019 - YTD*2023)
Table 11: Astex Pharmaceuticals, Inc.: Partnership Trend by Deal Type (2019 - YTD*2023)
Table 12: Astex Pharmaceuticals, Inc.: News and Events Summary
Table 13: Astex Pharmaceuticals, Inc.: Corporate Governance
Table 14: Astex Pharmaceuticals, Inc.: Financial Deals
Table 15: Astex Pharmaceuticals, Inc.: Market Developments
Table 16: Astex Pharmaceuticals, Inc.: Research & Development
Table 1: Astex Pharmaceuticals, Inc.: Key Facts
Table 2: Astex Pharmaceuticals, Inc.: Key Employees
Table 3: Astex Pharmaceuticals, Inc.: Company History
Table 4: Astex Pharmaceuticals, Inc.: Locations and Subsidiaries
Table 5: Astex Pharmaceuticals, Inc.: Key Competitors
Table 6: Astex Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (TTM*)
Table 7: Astex Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (2019 - YTD*2023)
Table 8: Astex Pharmaceuticals, Inc.: Targets and Partners
Table 9: Astex Pharmaceuticals, Inc.: Top Deals 2019 - 2023YTD*
Table 10: Astex Pharmaceuticals, Inc.: Partnership Volume and Value Trend (2019 - YTD*2023)
Table 11: Astex Pharmaceuticals, Inc.: Partnership Trend by Deal Type (2019 - YTD*2023)
Table 12: Astex Pharmaceuticals, Inc.: News and Events Summary
Table 13: Astex Pharmaceuticals, Inc.: Corporate Governance
Table 14: Astex Pharmaceuticals, Inc.: Financial Deals
Table 15: Astex Pharmaceuticals, Inc.: Market Developments
Table 16: Astex Pharmaceuticals, Inc.: Research & Development
LIST OF FIGURES
Figure 1: Astex Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (TTM*)
Figure 2: Astex Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (2019 - YTD*2023)
Figure 3: Astex Pharmaceuticals, Inc.: Partnership Volume and Value Trend (2019 - YTD*2023)
Figure 4: Astex Pharmaceuticals, Inc.: Partnership Trend by Deal Type (2019 - YTD*2023)
Figure 1: Astex Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (TTM*)
Figure 2: Astex Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (2019 - YTD*2023)
Figure 3: Astex Pharmaceuticals, Inc.: Partnership Volume and Value Trend (2019 - YTD*2023)
Figure 4: Astex Pharmaceuticals, Inc.: Partnership Trend by Deal Type (2019 - YTD*2023)